Medicare Advantage Tied to Less Use of Pricey Diabetes Drugs - Medscape

Data from more than 400,000 Medicare beneficiaries showed a significant link between less prescribing of SGLT2 inhibitors and GLP-1 agonists and enrollment in a Medicare Advantage plan.

Dr Utibe R. Essie US Medicare beneficiaries with type 2 diabetes who had health coverage through a Medicare Advantage (MA) plan received treatment with an SGLT2 inhibitor or GLP-1 receptor agonist s… [+6867 chars]

full article...